193 related articles for article (PubMed ID: 23146106)
1. Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients.
de Albuquerque A; Kubisch I; Stölzel U; Ernst D; Boese-Landgraf J; Breier G; Stamminger G; Fersis N; Kaul S
J Transl Med; 2012 Nov; 10():222. PubMed ID: 23146106
[TBL] [Abstract][Full Text] [Related]
2. Multimarker gene analysis of circulating tumor cells in pancreatic cancer patients: a feasibility study.
de Albuquerque A; Kubisch I; Breier G; Stamminger G; Fersis N; Eichler A; Kaul S; Stölzel U
Oncology; 2012; 82(1):3-10. PubMed ID: 22270149
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Role of a Multimarker Analysis of Circulating Tumor Cells in Advanced Gastric and Gastroesophageal Adenocarcinomas.
Kubisch I; de Albuquerque A; Schuppan D; Kaul S; Schaich M; Stölzel U
Oncology; 2015; 89(5):294-303. PubMed ID: 26315108
[TBL] [Abstract][Full Text] [Related]
4. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
Barbazán J; Muinelo-Romay L; Vieito M; Candamio S; Díaz-López A; Cano A; Gómez-Tato A; Casares de Cal Mde L; Abal M; López-López R
Int J Cancer; 2014 Dec; 135(11):2633-43. PubMed ID: 24752533
[TBL] [Abstract][Full Text] [Related]
5. Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach.
Ning Y; Hanna DL; Zhang W; Mendez A; Yang D; El-Khoueiry R; Matsusaka S; Sunakawa Y; Stremitzer S; Parekh A; Okazaki S; Berger MD; Barzi A; Lenz HJ
Mol Cancer Ther; 2015 Oct; 14(10):2401-8. PubMed ID: 26227487
[TBL] [Abstract][Full Text] [Related]
6. Relationship between circulating tumor cells and tumor response in colorectal cancer patients treated with chemotherapy: a meta-analysis.
Huang X; Gao P; Song Y; Sun J; Chen X; Zhao J; Liu J; Xu H; Wang Z
BMC Cancer; 2014 Dec; 14():976. PubMed ID: 25519477
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
Sastre J; Maestro ML; Gómez-España A; Rivera F; Valladares M; Massuti B; Benavides M; Gallén M; Marcuello E; Abad A; Arrivi A; Fernández-Martos C; González E; Tabernero JM; Vidaurreta M; Aranda E; Díaz-Rubio E
Oncologist; 2012; 17(7):947-55. PubMed ID: 22643538
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and Therapeutic Significance of Circulating Tumor Cell Phenotype Detection Based on Epithelial-Mesenchymal Transition Markers in Early and Midstage Colorectal Cancer First-Line Chemotherapy.
Lu G; Lu Z; Li C; Huang X; Luo Q
Comput Math Methods Med; 2021; 2021():2294562. PubMed ID: 34777560
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab.
Musella V; Pietrantonio F; Di Buduo E; Iacovelli R; Martinetti A; Sottotetti E; Bossi I; Maggi C; Di Bartolomeo M; de Braud F; Daidone MG; Cappelletti V
Int J Cancer; 2015 Sep; 137(6):1467-74. PubMed ID: 25704501
[TBL] [Abstract][Full Text] [Related]
10. Detection of circulating tumor cells with CK20 RT-PCR is an independent negative prognostic marker in colon cancer patients - a prospective study.
Hinz S; Hendricks A; Wittig A; Schafmayer C; Tepel J; Kalthoff H; Becker T; Röder C
BMC Cancer; 2017 Jan; 17(1):53. PubMed ID: 28086834
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff?
Gazzaniga P; Raimondi C; Gradilone A; Biondi Zoccai G; Nicolazzo C; Gandini O; Longo F; Tomao S; Lo Russo G; Seminara P; Vincenzi B; Chimenti I; Cristofanilli M; Frati L; Cortesi E
J Cancer Res Clin Oncol; 2013 Aug; 139(8):1411-6. PubMed ID: 23736274
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor cells as an independent prognostic factor in advanced colorectal cancer: a retrospective study in 121 patients.
Wang L; Zhou S; Zhang W; Wang J; Wang M; Hu X; Liu F; Zhang Y; Jiang B; Yuan H
Int J Colorectal Dis; 2019 Apr; 34(4):589-597. PubMed ID: 30627849
[TBL] [Abstract][Full Text] [Related]
13. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.
Cohen SJ; Punt CJ; Iannotti N; Saidman BH; Sabbath KD; Gabrail NY; Picus J; Morse M; Mitchell E; Miller MC; Doyle GV; Tissing H; Terstappen LW; Meropol NJ
J Clin Oncol; 2008 Jul; 26(19):3213-21. PubMed ID: 18591556
[TBL] [Abstract][Full Text] [Related]
14. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
Zhou J; Dong F; Cui F; Xu R; Tang X
Cancer Chemother Pharmacol; 2017 Apr; 79(4):825-833. PubMed ID: 28289866
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer.
Cohen SJ; Punt CJ; Iannotti N; Saidman BH; Sabbath KD; Gabrail NY; Picus J; Morse MA; Mitchell E; Miller MC; Doyle GV; Tissing H; Terstappen LW; Meropol NJ
Ann Oncol; 2009 Jul; 20(7):1223-9. PubMed ID: 19282466
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer.
Liu MC; Shields PG; Warren RD; Cohen P; Wilkinson M; Ottaviano YL; Rao SB; Eng-Wong J; Seillier-Moiseiwitsch F; Noone AM; Isaacs C
J Clin Oncol; 2009 Nov; 27(31):5153-9. PubMed ID: 19752342
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
De Laere B; Oeyen S; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; Van Kerckhove P; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff I; van Dam V; Brouwer A; van Dam PJ; Van den Eynden G; Rutten A; Sleijfer S; Vandebroek J; Van Laere S; Dirix L
Prostate; 2018 May; 78(6):435-445. PubMed ID: 29431193
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
Sastre J; Vidaurreta M; Gómez A; Rivera F; Massutí B; López MR; Abad A; Gallen M; Benavides M; Aranda E; Rubio ED;
Clin Colorectal Cancer; 2013 Dec; 12(4):280-6. PubMed ID: 24012456
[TBL] [Abstract][Full Text] [Related]
19. A Prognostic Model Based on Circulating Tumour Cells is Useful for Identifying the Poorest Survival Outcome in Patients with Metastatic Colorectal Cancer.
Chou WC; Wu MH; Chang PH; Hsu HC; Chang GJ; Huang WK; Wu CE; Hsieh JC
Int J Biol Sci; 2018; 14(2):137-146. PubMed ID: 29483832
[No Abstract] [Full Text] [Related]
20. Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: a meta-analysis and systematic review.
Yang C; Zou K; Zheng L; Xiong B
BMC Cancer; 2017 Nov; 17(1):725. PubMed ID: 29115932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
